TaiMed and AcedrA partner to commercialise Trogarzo
CONSUMER NEWS
Taimed Biologics, a publicly held Taiwanese biotechnology company, has signed deal with AcedrA BioPharmaceuticals to promote and commercialise Trogarzo (Ibalizumab-uiyk) in the Mena region.
Trogarzo has been approved by the US Food and Drug Administration to treat adults infected with Human Immunodeficiency Virus type 1 (HIV-1), a virus that causes Acquired Immune Deficiency Syndrome (AIDS).
Trogarzo is given with other HIV medicines when none of the standard combinations work to control the infection because the virus is resistant to them (multi-drug resistant HIV).
Broadening reach
“We are excited to broaden the reach of Trogarzo to HIV patients in new countries. AcedrA has a focus on working with rare and orphan drugs, and this agreement gives us a great opportunity to enter the Mena region over a short time frame,” said Dr Jimmy Chang, Chief Executive Officer of TaiMed.
“This is yet another significant step that aims to bring shareholder value through the realisation of the full commercial potential of Trogarzo.”
Under the terms of this agreement, AcedrA will be responsible in providing Trogarzo in reply to named-patient requests through which physicians can legally and ethically prescribe Trogarzo for patients prior to commercial availability. AcedrA, then, by a wider array of distribution activities, will be responsible for regulatory, sales, marketing, medical, and distribution in the Mena region.
Improving clinical outcomes
“AcedrA is responsibly engaged to serve communities where there are significant unmet therapeutic needs in the Mena region; we do believe that a synergy between AcedrA and TaiMed to make affordable the access to Trogarzo will improve clinical outcomes for HIV patients with limited therapeutic options,” said Dr Hosni STA, the Chief Executive Officer of AcedrA.
“We are committed to be a patient-centric company working closely with healthcare providers in the Mena region, and we will be pleased to partner with TaiMed strategically to improve patients' lives in the region.”--TradeArabia News Service
